Objective: Although transcatheter aortic valve implantation has been shown to be noninferior to surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk, the cost-effectiveness of this strategy in this population is unknown. Our objective was to conduct a cost-utility analysis comparing transcatheter aortic valve implantation with surgical aortic valve replacement in the population with intermediate risk severe aortic stenosis.
Traditionally, surgical aortic valve replacement (SAVR) was considered the gold standard for the treatment of severe aortic stenosis (AS). However, transcatheter aortic valve implantation (TAVI) has emerged as the treatment of choice for patients with severe symptomatic AS who are inoperable or at high surgical risk. 1, 2 Numerous previously published economic studies suggest that TAVI is costeffective in both the inoperable and high-risk populations. 3 The exponential growth of TAVI has led to indication expansion to low-risk patients. A landmark randomized clinical trial (RCT) conducted in patients with intermediate surgical risk ( 
Society of Thoracic Surgeons [STS] Predicted
Risk of Mortality at 30 days 4%-8%) showed noninferiority for TAVI compared with SAVR. 4 These findings have been reinforced by a number of propensity-matched studies and meta-analyses, 5 all of which have led to regulatory approval in the United States by the Food and Drug Administration (FDA) for this expanded indication.
The intermediate-risk patients differ from the higher-risk population in several ways that may affect costs and outcomes. In particular, given that this population may be younger with fewer comorbidities, complication rates and length of hospital stay are likely to be different. Although the intermediate-risk population represents an emerging indication for TAVI, the cost-effectiveness of TAVI compared with SAVR is not known in this patient population. Accordingly, to address this gap in knowledge, we conducted a formal cost-utility analysis incorporating both lifetime costs and benefits to determine the costeffectiveness of TAVI compared with SAVR in the intermediate-risk population from the Canadian thirdparty payer perspective.
MATERIALS AND METHODS Model Overview
A fully probabilistic Markov model with cycle lengths of 30 days was constructed from the Canadian third-party payer's perspective to estimate the cost and effectiveness of TAVI versus SAVR for the intermediate-risk patient population over a lifetime time horizon. Under Canada's universal health care plan, the provinces are responsible for all care delivery; thus, in Ontario, the third-party payer is the Ministry of Health and Long Term Care. The primary cost outcome was total lifetime cost measured in 2016 Canadian Dollars and the primary effectiveness outcome was quality-adjusted life-years (QALYs). QALYs were obtained by multiplying the time spent in a particular health state with the quality weight for that respective health state. The incremental cost-effectiveness ratio (ICER) was calculated by taking the differences in lifetime costs between the 2 treatment groups (ie, incremental costs) and dividing by the differences in lifetime benefits (ie, incremental effectiveness, measured in QALYs). All outcomes and costs were discounted at 1.5% per annum in accordance with the Canadian Agency for Drugs and Technologies in Health guidelines. 6 
Model Structure
All patients entered the model in the procedural state (TAVI or SAVR) and were at risk for clinically relevant short-term complications (major bleeding, acute kidney injury, vascular injury, atrial fibrillation, nondisabling stroke, rehospitalization) and long-term complications (death, dialysis, and disabling stroke).
After the procedural state, all patients transitioned into 1 of 4 long-term states (alive and well, disabling stroke, dialysis, or death) as shown in Figure 1 . Repeat hospitalization was a transition for which a patient would remain for a proportion of 1-cycle. Patients transitioned between these long-term states on the basis of efficacy data from the results of the recently published The Placement of Aortic Transcatheter Valve (PARTNER) 2 Trial. Transition probabilities between the alive and well state and the various complication states (excluding death) occurred only in the first 2 years of the model. After 2 years, we made the conservative assumption that the rates of complications were assumed to be equivalent in both the TAVI and SAVR arms. In addition, after 2 years, mortality rates in the model were based on 2010-2012 age-and gender-specific Canadian life tables given the absence of clinical trial data from the PARTNER 2 study beyond the 2-year follow-up. 7 When transition probabilities were not available from PARTNER 2, published results from the literature for similar patient populations were used as described next.
Clinical Efficacy Inputs
Trial overview. The PARTNER 2 Trial was a multicenter RCT of 57 centers in the United States and Canada comparing TAVI with SAVR in the intermediate surgical risk population (defined as STS Predicted Risk of Mortality 4 of 8% at 30 days). A total of 2032 patients at intermediate surgical risk were randomized to TAVI (n ¼ 1011) or SAVR (n ¼ 1021) and followed for the primary outcome of all-cause death or disabling stroke at 2 years using a noninferiority design. The average STS risk scores in both groups were similar (TAVI 5.8 AE 2.1, SAVR 5.8 AE 1.9), and the average age of the cohort was 81.5 AE 6.7 years and 81.7 AE 6.7 years in the TAVI and SAVR groups, respectively. In the TAVI group, patients underwent transfemoral or transthoracic placement of the balloon-expandable Sapien XT valve system (Edwards Lifesciences, Irvine, Calif).
Efficacy end points. The 30-day clinical end points were obtained from the PARTNER 2 Trial intention-to-treat cohort: death from any cause, any stroke, disabling stroke, nondisabling stroke, rehospitalization, major vascular complication, life-threatening or disabling bleed, acute kidney injury, and new-onset atrial fibrillation (Table E1) . After 30 days, transition probabilities were based on 1-year and 2-year end points from the trial. We excluded patients who had an event at 30 days and 1 year from both the numerator and denominator of cumulative long-term probabilities (1 year and 2 years, respectively) to avoid double counting patient events as described in a previous cost-analysis. 8 The proportion of patients with acute kidney injury progressing to dialysis was not provided in the PARTNER 2 Trial and was estimated from the PARTNER 1A trial; we used the same proportion in both groups. 2 The probability of death during long-term dialysis was estimated from the published literature, 9 and the probability of death in patients with long-term strokes was also obtained from the literature. 10 Cost inputs. Up-front procedural costs included the following: TAVI system, SAVR valve, interventional cardiology procedural fees, surgeon fee, surgical assistant fee, anesthesiologist fee, ward, and intensive care unit (ICU) stay (Table 1) . On the basis of input from TAVI implanters, the corresponding billing codes from the Ontario Schedule of Benefits used for TAVI and SAVR were determined. 11 Utilities and quality of life inputs. Quality of life (QoL) utilities for the different health states were obtained from the literature given the absence of specific QoL data from the PARTNER 2 trial (Table 2) . [16] [17] [18] [19] [20] [21] We used published EuroQol data from the PARTNER 1A trial 21 as a surrogate for baseline, 6-month, and 1-year utilities in the alive/well state in our model. Utilities for long-term Markov states were estimated from the literature for hospitalization, 20 dialysis, 19 and disabling stroke. 18 For periprocedural complications, we assigned a 1-time decrement in utility (ie, disutility), which represented a decreased QoL for that particular complication. These disutilities were estimated from a prospective observational cohort study of TAVI and SAVR cases published in the literature for major bleeding, vascular complications, acute kidney injury, atrial fibrillation, and nondisabling stroke. 16 The disutility for hospitalization was estimated from a French cost-effectiveness model of patients with atrial fibrillation. 17 Base-case and sensitivity analyses. The base case was conducted fully probabilistically, with 10,000 Monte-Carlo simulations. All inputs described were sampled from distributions, with the expected value being the mean from the studies and the standard deviations from the source literature. For any data without standard deviations, we used one third of the point estimate as the standard deviation, as previously described. 22 For all probabilities and utilities, a beta distribution was used, whereas a gamma distribution was used for costs, procedural length, and hospital length of stay. The average costs and effects for the 10,000 simulations were used to calculate the base-case results and ICER. Parameter uncertainty was represented by a cost-effectiveness acceptability curve, showing the proportion of the simulations that favored TAVI at different willingness-to-pay (WTP) thresholds.
A series of deterministic 1-way sensitivity analyses were also performed to examine the impact of key parameters in the model on the ICER. For probabilities, 95% confidence intervals were derived, and the lower and upper boundaries were used as the low and high values in the deterministic 1-way SA. For costs, the lower and upper values were AE50% of the estimated costs. In addition to the base-case analysis ICER, we performed a scenario analysis restricted to the transfemoral-access only cohort compared with the SAVR cohort (n ¼ 775 in both groups). Efficacy inputs were informed from the periprocedural, 1-year, and 2-year event rates from the transfemoral access and SAVR group from the PARTNER 2 Trial. 4 
RESULTS
In the base-case analysis, the index hospitalization cost in the TAVI group was $40,274 compared with $29,856 in the SAVR group. With 1.5% global discounting, the total lifetime cost was $46,904 AE $4038 and $36,356 AE $7309 in the TAVI and SAVR groups, respectively. The life-years gained were 7.57 AE 0.10 and 7.42 AE 0.11 for TAVI and SAVR, respectively. When QoL was taken into account, the QALYs gained were 5.63 AE 1.47 and 5.40 AE 1.47 for TAVI and SAVR, respectively (Table 3) . Thus, the incremental cost was $10,547 and the incremental gain in QALY was 0.23. This resulted in an ICER of $46,083/QALY after discounting.
The total undiscounted lifetime costs were $47,054 AE $4113 and $36,478 AE 7261 for TAVI and SAVR, respectively, for a difference in total costs of $10,576. The total undiscounted QALYs gained for TAVI and SAVR were 6.18 AE 1.60 and 5.92 AE 1.63, respectively, resulting in a difference of 0.27 QALYs. Thus, the ICER without discounting was $39,661/QALY.
In 1-way sensitivity analyses, costs and procedural complication rate thresholds were calculated for a WTP of $50,000/QALY gained. The ICER exceeded $50,000/ QALY gained when the cost of the TAVI valve system was greater than $25,100 (compared with base case of $24,000) or when TAVI ICU length of stay was greater than 2.3 days (base case of 2 days). For procedural complications, the ICER was greater than $50,000/QALY when the rate of periprocedural mortality in the TAVI was greater than 4.2% or less than 3.6% in the SAVR arm and the rate of periprocedural stroke in the SAVR was less than 5.5% and greater than 6.0% in the TAVI arm (base-case complication rates shown in Table E1 ). The results of the probabilistic analysis indicated that approximately 52.7% and 55.4% of the 10,000 iterations fell below the $50,000 and $100,000 per QALY gained WTP threshold when TAVI was compared with SAVR, respectively. The costeffectiveness acceptability curve for TAVI versus SAVR, with a WTP threshold of $0 to $200,000, is shown in Figure 2 .
In the transfemoral access scenario analysis, the index hospitalization cost was $40,210 in the transfemoral TAVI arm and $29,632 in the SAVR arm, and lifetime costs were $46,129 AE $4161 and $36,314 AE 7435, respectively. The QALYs gained was 5.84 AE 1.53 and 5.44 AE 1.48 in TAVI and SAVR, respectively, yielding a difference of 0.40 gained for TAVI. The ICER, when restricted to the comparison of transfemoral TAVI to SAVR, was $24,790/ QALY.
DISCUSSION
In this cost-utility analysis based on contemporary evidence, we have shown that TAVI may be cost-effective in comparison with SAVR in the intermediate surgical risk population with a favorable ICER of $46,083/QALY gained. This builds on numerous previous studies that have established that TAVI is an economically attractive option in the high surgical risk or the inoperable population. 3 However, there was moderate-to-high uncertainty in our analyses, with the cost-effectiveness particularly sensitive to the cost of the TAVI prosthesis and the length of ICU stay.
TAVI is a Class IIa recommendation for the intermediaterisk population with severe AS in the most recent American Heart Association guidelines (2017). 23 The intermediate surgical risk population represents a different population compared with the inoperable and high surgical risk population because these patients have substantially less comorbidities. 1, 2, 4 As such, their derived benefit from TAVI and associated costs differ. There is only 1 other study that compared costs in the intermediate-risk population using propensity score matching of 42 pairs of patients at a single Dutch institution. 24 In this study, Osnabrugge and colleagues 24 found that initial in-hospital costs were higher in TAVI compared with the SAVR population (V40,802 vs V33,354; P ¼ .010) and higher at 1-year follow-up (total cost: V46,217 vs V35,511; P ¼ .009). The study did not consider effectiveness, but simply compared the costs of the interventions in a small sample of patients from a single institution over a 1-year time horizon. In contrast, our study used the recently published PARTNER 2 multicenter RCT data with more than 2000 patients to determine costs and effectiveness in a Markov model over a lifetime time horizon. Similar to the study by Osnabrugge and colleagues, 24 our overall in-hospital costs at 30 days and lifetime follow-up costs were higher in the TAVI group compared with the SAVR group. Although costs were higher in the TAVI groups, the patients also accrued more QALYs over the lifetime horizon compared with SAVR in the basecase analysis. The cost findings of this study were similar to those reported by Wijeysundera and colleagues, 25 Consistent with previous studies, 8, 25 our study found that the major cost-drivers were the cost of the TAVI prosthesis (TAVI vs SAVR: $24,000 vs $$6000 CAD), rates of complications, and length of stay in the ICU in our sensitivity analysis. Of note, TAVI was no longer cost-effective when the TAVI valve system cost was increased by $1100 or when ICU LOS increased by 0.3 days. This highlights the impact of parameter uncertainty on the base-case results and the importance of conducting a fully probabilistic analysis such that all point estimates are drawn from specific distributions to address uncertainty. Nonetheless, our findings suggest that cost-savings through reduced ICU and hospital LOS help offset the higher acquisition cost of the TAVI valve system. In addition, the sensitivity of our analyses to these parameters reinforces the need for early discharge algorithms for patients undergoing TAVI to optimize length of stay, as well as increased market competition to reduce acquisitions costs for the prostheses themselves.
26
The American College of Cardiology and American Heart Association consider a WTP threshold of greater than 3 times a country's gross domestic product (GDP) to be of low value, whereas a threshold between 1 and 3 times GDP is of intermediate value and less than a country's GDP to be high value. 27 Thus, in both the Canadian and American perspective, ICERS less than $50,000/QALY represent high value and ICERs between $50,000 and $150,000/ QALY represent intermediate value. Although the basecase analysis of our study would suggest that TAVI is a cost-effective alternative compared with SAVR in the intermediate-risk population, our probabilistic sensitivity analysis showed that TAVI was the preferred option in only 52.6% of simulations when the WTP threshold was $50,000/QALY gained ( Figure 2 ). There was variation in terms of effectiveness and the ICER was inferior to SAVR in 41.7% of cases, representing moderate-to-high uncertainty around efficacy point estimates and the noninferiority nature of the results. Moreover, as highlighted earlier, even relatively small changes in the cost of the TAVI prosthesis or length of stay will have substantial impact on the overall cost-effectiveness. This underscores the limited evidence base in the intermediate-risk population and reinforces the need for additional clinical trials in this area.
Consistent with findings in the literature, the ICER in our scenario analysis of a transfemoral only cohort was lower than that of the entire cohort (transfemoral and transapical access) when compared with SAVR. 28 The literature has shown lower index procedural and hospitalization costs along with improved outcomes in the transfemoral group compared with the transapical cohort. 25 This difference likely is reflective of the older and more comorbid nature of the transapical cohort along with the less-invasiveness nature of transfemoral TAVI. Nonetheless, this reaffirms that transfemoral TAVI remains the preferred choice for access when possible. However, these results should be interpreted in the context of the design of the PARTNER 2 trial: The primary outcome was for the entire cohort, and secondary analyses considered stratifying by route of access.
The
A shift in human resources also may be needed as staff require additional training to perform these specialized procedures. These additional resources are typically not incorporated into a cost-utility analysis, but nonetheless are critical considerations.
Study Limitations
The interpretation of the results of our cost-utility analysis must be taken in the context of some limitations that merit discussion. Derivation of the initial procedural costs for SAVR and TAVI was obtained from expert opinion and thus may not be generalizable to other jurisdictions. Regardless, the rigor in costing data in the current study is confirmed because reported procedural costs were similar to previously published work from Ontario using microcosting data. 25 Nonetheless, we acknowledge that the cost of medical care in the United States is substantially higher than that of the Canadian health care system. Although the costs may be higher in the US setting, they will likely be higher in both the TAVI and SAVR arms, so the incremental cost, and therefore ICER, would remain similar. Point estimates may vary slightly because of different cost inputs, but we do not expect a directional change. Furthermore, there was uncertainty around utility inputs in our study because the PARTNER 2 trial has yet to publish their utility study. However, the data we used from the PARTNER 1A trial of high-risk patients followed a similar pattern observed in other studies published in the literature, with patients in the TAVI group showing an earlier and more rapid improvement in QoL within the first 3 months of the procedure. 21 ,32 A major limitation of our model is that the TAVI valve durability remains uncertain in the intermediate-risk population because the study only followed patients to 2 years. Currently, the best evidence to support valve durability is derived from the PARTNER 1A trial; there were no cases of structural valve deterioration at 5 years. 33 Although patients in PARTNER 1A were older (mean age, 83.6-84.5 years) than patients in PARTNER 2 (mean age, 81.5-81.7 years), the average life years gained in our model was 7 years.
2,4 Thus, we thought that valve durability would be similar to surgery over the lifetime of these octogenarians. However, extended follow-up of these patients will be of critical importance for low-risk young patients as TAVI indications evolve. Furthermore, findings from this study are generalizable to the intermediate-risk population only. The low-risk population may present with their own efficacy rates, complication rates, and length of stay that may affect the overall cost-effectiveness of TAVI. Last, PARTNER II only provided outcomes to 2 years; thus, after 2 years, we estimated the rate of mortality from Canadian life tables and assumed that these patients had a similar life expectancy to Canadians of similar age and gender. This methodology is consistent with previously published cost-effectiveness analyses. Furthermore, work by Mihaljevic and colleagues 34 showed that life expectancy is restored to that of age-and gendermatched controls in patients aged more than 65 years undergoing aortic valve replacement for AS.
CONCLUSIONS
From the perspective of the Canadian health care system, compared with SAVR, TAVI may be a cost-effective option for the treatment of severe AS in the intermediate surgical risk population with an ICER of $46,083/QALY in the base-case analysis. However, there was moderate to high uncertainty in our parameter estimates; only 52.7% and 55.4% of the ICERS in our simulations were below the WTP thresholds of $50,000 and $100,000/QALY, respectively. This meant that 44.6% to 47.3% of cases were not cost-effective. As such, despite the potential patient preference for a less-invasive approach, before widespread expansion of TAVI indications to lower-risk patients, more rigorous clinical evidence is needed. TAVR has been shown to be cost-effective against medical therapy in the inoperable population and against SAVR or SAVR in the high surgical risk group. The recently published PARTNER 2 trials show noninferiority between TAVR and surgery at 30 days and 2 years. This was in the intermediate surgical risk population in whom the STS predicted risk of mortality was 4% to 8%. On the basis of this evidence, the FDA has approved TAVR for the intermediate surgical risk population, and the most recent American Heart Association (AHA) valve guidelines have now made TAVR a class 2 recommendation for the intermediate-risk population. However, the cost-effectiveness has not been established in this group. As such, it is both relevant and timely to explore the cost-effectiveness of TAVR in the intermediate surgical risk group compared with surgery. Our population of interest is patients with severe AS at intermediate surgical risk. This is the PARTNER 2 cohort. Our intervention is the balloon-expandable TAVR performed transfemorally or transthoracically. Our comparator is surgery, and our outcomes of interest include lifetime effectiveness as measured by quality adjusted life years or ''QALYs'' and lifetime costs as measured in 2016 Canadian dollars. Our primary outcome is the ICER. This is calculated by taking the difference in lifetime costs between TAVR and surgery, also known as the incremental cost, divided by the difference in lifetime effectiveness between TAVR and surgery or the incremental effectiveness measured as QALYs. This gives us results in units of dollars per QALYs gained or QALYs gained. We used a fully probabilistic Markov model with 30-day cycle lengths, and we took the perspective of a third-party pair, which in our case is the Ontario Ministry of Health. We undertook a lifetime time horizon, and all costs and effectiveness were discounted at 1.5% per annum per the most recent guidelines. Our efficacy inputs came from the PARTNER 2 Trial, and our short-term cost inputs were mainly obtained from the Canadian Institute of Health Information, using their patient cost estimator, and from a variety of other sources. Our long-term costs and QoL inputs were obtained through a review of the literature. The following set of animations will describe the Markov model. We take a theoretical cohort of patients at intermediate surgical risk with severe AS. We model what happens to them when they undergo TAVR. We also model what happens to these patients when they undergo surgery. We then compare the 2 arms. Here we'll focus on the TAVR group, but the same thing happens with the surgical patients as well. All patients start off in the procedural state. Patients who undergo TAVR are at risk for a set of complications, including atrial fibrillation, acute kidney injury, stroke, rehospitalization, bleeding, and vascular injury. These are short-term states. They are also at risk for long-term complications, including dialysis, permanent stroke, and rehospitalization; they can also die as a result of the procedure or they can be discharged alive and well. With each of these complications, there are costs associated with it, and there are QoL utilities that are associated with it. The probabilities of being in each of these states are determined from the PARTNER 2 30-day outcomes. We run the same analysis for the surgical arm. After 30 days, the patients enter their long-term state. They enter their respective long-term state on the basis of the complications that took place in the first 30 days. They move along these different states, again from the probabilities from the PARTNER 2 1-and 2-year data. There are costs associated with each of these states, and there are utilities associated with each of these states or QoL metrics. We run the model until everyone is in the dead or the absorbing state, at which point the model stops, and we tabulate all costs and benefits for each arm and we compare the two.
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In our base-case analysis, we used a fully probabilistic Markov model, which meant that all inputs were varied on the basis of its distribution in each iteration. The results shown are the average of 10,000 iterations or runs of the model. We also performed sensitivity analyses. One-way sensitivity analyses were performed, meaning that key parameters were varied one at a time to assess the impact on the ICER. We also looked at a transfemoral only cohort analysis using the subgroup analysis from the PARTNER 2 trial. These are the results of our base-case analysis.
Here we look at discounted costs and QALYs. We show that the total lifetime cost in the TAVR arm was $46,000, whereas in the surgical arm it was $36,000. Total lifetime QALYs gained were also higher in the TAVR group at 5.63, and it was 5.40 in the SAVR group. This meant that both costs and incremental effectiveness were higher in the TAVR arm. This yielded a final ICER of $46,000 per QALY gained. To address the certainty, we used a probabilistic analysis. Any points that land in this quadrant would be more costly and effective. Any points in this quadrant would be more costly and less effective. Any points in this quadrant are less costly and less effective, and any points here would be less costly, but more effective. Each blue dot here represents 1 run of the model. There are 10,000 dots, 10,000 iterations of the model. If we take the average of those dots, we get our base-case analysis of $46,000 per QALY. These 2 lines represent common willingness to pay thresholds by reimbursement agencies of $50,000 and $100,000 per QALY. Points to the right of those lines would be considered cost-effective. As you can see here, the cloud of blue dots are above the horizontal axis, meaning that on average, TAVR was more costly and there was a spread on the horizontal axis for incremental effectiveness, meaning that efficacy was evenly distributed between the 2 arms. We can also represent the previous graphic using a cost-effectiveness acceptability curve, and the red line here is the TAVR group. We show that they cost approximately $46,000, which was our base-case ICER; approximately 50% of the iterations would be cost-effective at that point. As the willingness to pay increases, the number of iterations that are cost-effective tapers to approximately 56%.
Here are the results of our 1-way sensitivity analysis. This is a tornado diagram. It shows that the cost of the TAVR valve has a great impact on the base-case ICER. It also shows that the ICU length of stay has an impact on our base-case ICER as well, along with 30-day mortality in both the surgical and TAVR arms. These are the results of our subgroup analysis of the transfemoral access only. We show again that the total lifetime costs are higher in the TAVR group but similar to the base-case analysis. However, the number of QALYs gained are higher in the TAVR group compared with the base-case analysis. This meant that the denominator is larger and as such yielded a lower ICER, approximately $24,000 per QALYs. In our analysis, we showed that TAVR was cost-effective compared with surgery, at common willingness to pay thresholds. Compared with previous work that has shown cost-effectiveness in the inoperable population and the high-risk population, our ICER is slightly less than that of groups already being reimbursed. However, there was modest uncertainty surrounding the ICER; only 53% of the ICERs fell below a $50,000 threshold. I think this reflects a noninferiority nature of the data, and finally, the high acquisition costs of the TAVR valve may be offset by decreased ICU length of stay in the TAVR group and represents an area for TAVR improvement. However, the results of our study must be interpreted in the context of some limitations. The PARTNER-PARTNER 2 QoL data have not been published. As such, we had to use QoL data from previously published literature, the PARTNER-PARTNER 1A trial. There is a lack of perspective costing data from the PARTNER-PARTNER 2 trial; nonetheless, our reported costs are similar to published Ontario micro-costing data, and we believe that our methodology is rigorous.
Finally, contemporary postoperative practices have changed for TAVR, especially in 2017. There are early discharge algorithms, and in some centers, the ICU is bypassed entirely. This would reduce costs for the TAVR group.
In conclusion, we showed that TAVR is cost-effective, compared with surgery, at a willingness to pay a threshold of $50,000 per QALY in the Canadian setting. There remain uncertainties surrounding the base-case ICER, and transfemoral access remains the preferred approach in patients undergoing TAVR. This was driven by improved effectiveness. Reduction in the cost of TAVR system and the reduced ICU length of stay will improve the cost-effectiveness of this technology in the future. Dr Tam. That's a great point that you brought up with regard to valve durability, and you're right, in the PARTNER 2 trial, they only followed their patients to 2 years, so there's limited evidence to support valve durability in that study. To address your question with regard to reintervention, we didn't look at late reintervention in our model because it was actually small, the numbers, in the PARTNER-PARTNER 2 trial. I think it was 1%, and it was similar between both arms, so we didn't include that in our model. With respect to our assumptions with using valve durability data, I think the best evidence for this probably comes from the PARTNER 1A trial, and they have 5-year data to show that there wasn't really a difference in structural valve deterioration between the 2 arms. However, the patients in PARTNER 1 were older and had more comorbidities. In our model, our patients were 80 years old, and in our model, they lived for an additional 7 years when QoL was not accounted for. So, I think 7 and 5 years are similar, and it's a reasonable assumption that these patients probably won't have any structural valve deterioration within that timeframe. But again, you're right, it is a limitation of our study and requires further work, but I think this becomes more relevant when we look at expending indications for TAVR to younger patients and low-risk patients, and I think this becomes critical to address then.
Dr Fischbein. For the second question, this cost analysis may be device specific. For example, will TAVR be as costeffective for the core valve where we know that the pacemaker rate is higher. Pacemakers will increase your numerator, the cost, and will also affect the quality, because these patients will be less satisfied as well.
Dr Tam. That's another excellent point, and this is actually something I'm really excited about because our group has just studied this and we've looked at a cost utility model for a self-expanding TAVR system using the SURTAVI data. We've recently submitted this to the STS as an abstract, so unfortunately I can't really describe the results for our findings for that study, but I do agree that you're right, this would affect the ICER, both the denominator and the numerator.
Dr Fischbein. The analysis is sensitive, as you mentioned, to changes in ICU length of stay, as well as in the step-down unit, and complications from the procedures, and so as you mentioned, in many institutions, patients are, especially the transfemorals, not going to the ICU. Instead, they're going directly to the step-down unit, and probably leaving the hospital in 2 or 3 days. But can these cost and practice patterns really be generalized to the ever-expanding number of TAVR programs that we're seeing even in the United States. I think there's more than 490 in 2016. So efficiency does come with practice, and as we see these smaller centers open, will they be able to discharge patients as quickly and have as low a complication rate, so will this cost analysis apply to everyone? Dr Tam. Right. One of the limitations of any cost-effectiveness analysis is that it must be interpreted in a certain context and in certain jurisdictions, so it might not always apply. We use Canadian costs, but it's a single-payer system and a nonprofit system as well. But with respect to your question about efficiency, can smaller-volume hospitals discharge patients the same as large-volume hospitals? I think they can. I think in the United States, where you have a competitive marketplace and bundle payment schemes becoming more popular, this will force hospitals to become efficient when they do a procedure like TAVR. You also have health maintenance organizations that are good at organizing health care, and they might just combine centers that do TAVR or have TAVR centers of excellence once they realize that there are certain volume associations with outcomes.
Dr R. Shemin (Los Angeles, Calif). Can you tell us whether you've compared your cost-effective analysis to other countries that have also done a similar study in their health care systems, and are there any differences or advantages that you'd like to say come from being able to do this type of study in Canada with a single-payer system? Dr Tam. That's an excellent question. This is actually the first cost-effectiveness analysis in the intermediate surgical risk population. This has been well studied in both the inoperable risk group, in which the risk of mortality is greater than 50% at 30 days, and the high surgical risk group across many jurisdictions, so in Europe, Canada, and even in the United States, this has been published. For most countries in the inoperable population, compared with medical therapy, it's very cost-effective, or even something we call dominant, where it's less costly but more effective. In the high surgical risk population, it does depend on jurisdiction as well. Is there a benefit to performing this in the Canadian setting? I think there is. The costs are fairly uniform in terms of how we source our costs and that adds rigor to our costing methodology, and we were able to show that using our costing methodology was similar to published Canadian data from previous groups.
Dr Shemin. To follow up on one of Dr Fischbein's questions, is there strong regionalization of TAVR sites in Canada? In the United States, we have an increasing number of programs that are doing what's called conscious sedation, where they're eliminating general anesthesia, patients are coming in the same day, limiting the ICU stay, which is one of your big drivers of cost, and how prevalent is that in your Canadian data, because clearly that's going to continue to advantage the TAVR population.
Dr Tam. Yes, that's an insightful comment and completely correct; as we remove the ICU from the equation, we know that the ICER will decrease. In our sensitivity analysis, we showed that if we just reduced the ICU length of stay in the TAVR group to 1 day, the ICER probably decreases to less than $40,000 per QALY, so it's certainly affected. In Canada, there's approximately 27 centers that do TAVR. Our population is approximately 30 million, so one tenth of the United States. Most of these centers do less than 100 cases a year, and there are approximately 2 or 3 centers that do more than 100. A lot of them do use conscious sedation, and most of them are using step-down now instead of the ICU. So certainly, practices have changed since the publication of the PARTNER 2 trial.
Dr N. Mokadam. You acknowledged in the article that because dialysis was not reported in the PARTNER 2 trial, you used PARTNER 1 assumptions. Those are different patients, and do you think that assumption is valid? Dr Tam. Yes, that's a good point, and we struggled a bit with that when we were developing this model, but as with any economic model, there are limitations, especially when it's not built into a clinical trial. Sometimes we use what's called a patchwork to come up with a good model, and we use what we would consider the most similar group of patients to our model patients. I know PARTNER 1 patients are at slightly higher risk and they're slightly older, they're about 83 years old compared with 80 years. But if you have acute kidney injury, and you end up going to dialysis, I think the QoL outcomes are similar for that group. It is a smaller number of patients, though. 
